Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=29098166
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A
Review in Type 2 Diabetes
#MMPMID29098166
Mega C
; Teixeira-de-Lemos E
; Fernandes R
; Reis F
J Diabetes Res
2017[]; 2017
(?): 5164292
PMID29098166
show ga
Diabetic nephropathy (DN) is now the single commonest cause of end-stage renal
disease (ESRD) worldwide and one of the main causes of death in diabetic
patients. It is also acknowledged as an independent risk factor for
cardiovascular disease (CVD). Since sitagliptin was approved, many studies have
been carried out revealing its ability to not only improve metabolic control but
also ameliorate dysfunction in various diabetes-targeted organs, especially the
kidney, due to putative underlying cytoprotective properties, namely, its
antiapoptotic, antioxidant, anti-inflammatory, and antifibrotic properties.
Despite overall recommendations, many patients spend a long time well outside the
recommended glycaemic range and, therefore, have an increased risk for developing
micro- and macrovascular complications. Currently, it is becoming clearer that
type 2 diabetes mellitus (T2DM) management must envision not only the improvement
in glycaemic control but also, and particularly, the prevention of pancreatic
deterioration and the evolution of complications, such as DN. This review aims to
provide an overview of the current knowledge in the field of renoprotective
actions of sitagliptin, namely, improvement in diabetic dysmetabolism,
hemodynamic factors, renal function, diabetic kidney lesions, and cytoprotective
properties.
|Diabetes Mellitus, Type 2/*drug therapy
[MESH]
|Diabetic Nephropathies/*drug therapy
[MESH]
|Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use
[MESH]
free
free
free
